AI eye scanner could prevent blindness in millions with diabetes

NCT ID NCT07151001

Recruiting now Diagnosis Sponsor: iHealthScreen Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests an artificial intelligence system called iPredict-DR that analyzes retinal photos to detect diabetic retinopathy, a leading cause of blindness. Researchers will enroll 922 adults with diabetes at primary care and endocrinology clinics. The AI's accuracy will be compared against human experts to see if it can reliably identify early signs of eye damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iPredict-DR AI software
What this could lead to: If successful, this AI tool could allow routine screening for diabetic eye disease in primary care clinics, catching it early before vision loss occurs.
What could go wrong: This is a pivotal trial, but the AI must prove it matches expert ophthalmologists. If accuracy falls short, it may not be adopted widely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus diabetic retinopathy disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES DIABETIC RETINOPATHY

Contacts and locations

Locations

iHealthScreen Inc.
RECRUITING

Richmond Hill, New York, 11418, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.